OncoMatch/Clinical Trials/NCT06240728
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
Is NCT06240728 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies NPX887 for metastatic malignant neoplasm.
Treatment: NPX887 — NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2) that may potentiate an anti-tumor immune response. The goal of this first-in-human study is to learn whether NPX887 is safe and tolerable and shows a preliminary efficacy in participants with B7-H7 (HHLA2) expressing tumors at selected dose(s). The main questions it aims to answer are: * what is an appropriate dose to be given to participants? * are the side effects of treatment manageable? * what is the preliminary anti-tumor activities? Participants who are treated will receive an intravenous (IV) infusion of NPX887 if their disease has not progressed, and be closely monitored by the treating physicians.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: HHLA2 expression (confirmed expression in tumor by IHC (central lab, pre-screening))
participants must have confirmed B7-H7/HHLA2 expression in their tumor determined via archival tissue IHC testing through a central lab (pre-screening)
Required: EGFR mutation
EGFR mutant lung adenocarcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center · Baltimore, Maryland
- Beth Israel Deaconess Medical Center (BIDMC) · Boston, Massachusetts
- Albert Einstein Medical College Montefiore Medical Center · The Bronx, New York
- MD Anderson Cancer Center · Houston, Texas
- Next Oncology · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify